UNSPSC 51182036: Oxymetholone

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C21H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L76T0ZCA8K, chemically known as androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17methyl-, (5.alpha.,17.beta.) but generally known as oxymetholone, which bears US NIH Compound Identifier 9902. European Medicines Agency schedules Oxymetholone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09568MIG.

UNSPSC 51182036 Oxymetholone, a Commodity code, covers the supply of this specific anabolic steroid pharmaceutical product to state and local government health facilities and agencies. State and local procurement under this code centers on manufacturer contracts for generic pharmaceutical supplies distributed through authorized drug wholesalers to participating state, county, and municipal health systems, correctional facilities, and other public-sector medical providers. The code sits within broader pharmaceutical procurement frameworks where jurisdictions establish multi-year standing agreements with manufacturers, typically requiring cGMP certification, FDA compliance, Drug Supply Chain Security Act compliance, and pricing flexibility through tiered net-pricing or WAC-minus structures. Issuing bodies soliciting under this code include state departments of administration and multistate cooperative purchasing alliances that coordinate pharmaceutical procurement across multiple jurisdictions to achieve volume-based pricing advantages.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The solicitation required manufacturers to supply comprehensive pricing for identified pharmaceutical products with specific National Drug Codes, maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, or Morris & Dickson), certify cGMP and DSCSA compliance, and carry commercial general liability insurance of $5 million per occurrence. The contract term is two years for new vendors with optional MMCAP extensions, with awarded vendors effective July 1, 2026. Evaluation weighted price competitiveness at 75 percent, fixed pricing at 10 percent, and administrative compliance requirements (EDI capability, format adherence, administrative-fee agreement) at 15 percent combined, with vendors liable for performance penalties ranging from $200 to $1,500 per violation.